Repligen Corporation, a leading life sciences company specializing in bioprocessing technology, recently unveiled its financial results for the second quarter of 2025. The company’s President and CEO, Olivier Loeillot, expressed satisfaction with the quarter’s performance, highlighting a remarkable 17% organic non-COVID growth. This growth was driven by robust demand in both consumables and capital equipment, as well as strong performance in the biopharma sector. Repligen’s consistent order growth over the past quarters showcases the effectiveness of its strategic approach, resulting in a solid 15% organic non-COVID growth in the first half of 2025. Encouraged by this positive momentum, Repligen has raised the midpoint of its organic growth guidance for the remainder of 2025, despite facing recent challenges from new modalities.
The company’s financial standing at the end of June 2025 reflected cash, cash equivalents, and short-term investments amounting to $709 million. Looking ahead, Repligen’s updated revenue guidance now anticipates a 1% tailwind from foreign currency, a shift from the previous expectation of a 1.5% headwind. Additionally, the guidance factors in a modest impact from tariff surcharges. To delve deeper into Repligen’s performance and strategic outlook, the company will be hosting a conference call and webcast on July 29, 2025, at 8:30 a.m. ET. The event will cover the second quarter financial results, corporate updates, and the financial guidance for the full year 2025. Participants can join the call by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers. No passcode is required for the live call. Alternatively, the webcast will be accessible through the Investor Relations section of Repligen’s website. Both the conference call and webcast will be archived for future reference, with replay options available for interested listeners.
Read more from finanznachrichten.de